TrialBMJ open diabetes research & care2020

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.

John B Buse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.